Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience

Transplantation. 2022 Jul 1;106(7):e343-e345. doi: 10.1097/TP.0000000000004150. Epub 2022 Mar 24.

Authors

Affiliations

¹ Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples "Federico II," Naples, Italy.
² Department of Public Health, Section of Nephrology, University of Naples "Federico II," Naples, Italy.
³ Department of Clinical Medicine and Surgery, Gastroenterology and Hepatology Unit, University of Naples "Federico II," Naples, Italy.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Neutralizing
COVID-19*
Humans
Organ Transplantation* / adverse effects
SARS-CoV-2
Transplant Recipients

Substances

Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
sotrovimab